Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma
- 1 February 1998
- journal article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 38 (2) , 207-220
- https://doi.org/10.1016/s0190-9622(98)70597-3
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: A 10-year experience at a single institutionJournal of the American Academy of Dermatology, 1996
- Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapyJournal of the American Academy of Dermatology, 1996
- Photopheresis therapy for cutaneous T-cell lymphomaJournal of the American Academy of Dermatology, 1996
- Proliferation cell nuclear antigen and soluble interleukin 2 receptor levels in cutaneous T cell lymphoma: correlation with advanced clinical diseasesJournal of Dermatological Science, 1994
- Mycosis fungoides: clinical and histologic features, staging, evaluation, and approach to treatmentCA: A Cancer Journal for Clinicians, 1993
- Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapyJournal of the American Academy of Dermatology, 1992
- Photopheresis for the treatment of cutaneous T cell lymphomaPublished by Elsevier ,1990
- Clinical features associated with transformation of cerebriform T‐cell lymphoma to a large cell processHematological Oncology, 1990
- Treatment of Cutaneous T-Cell Lymphoma by Extracorporeal PhotochemotherapyNew England Journal of Medicine, 1987
- Functional and phenotypic comparison of human T cell leukemia/lymphoma virus positive adult T cell leukemia with human T cell leukemia/lymphoma virus negative Sézary leukemia, and their distinction using anti-Tac. Monoclonal antibody identifying the human receptor for T cell growth factor.Journal of Clinical Investigation, 1984